Drug intelligence / Profile preview

sinotecan

Development stage: Phase 1
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Intravenous

Overview

Sinotecan is a small molecule drug that functions as a topoisomerase I (TOP1) inhibitor. It was initially developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The primary mechanism of action involves inhibiting the enzyme topoisomerase I, which is essential for DNA replication and transcription, thereby exerting antitumor effects. Sinotecan has been investigated in clinical studies to assess its maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics[1][2]. Its main indication appears to be in oncology.

Other names: sinotecean

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on sinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sinotecan.

Explore the full profile